Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20018464 | 1.00 | GLP1R (0.44) | GLP1RNOD1KMT2AL3MBTL1P2RY12 | |
| SCHEMBL16010862 | 0.90 | FOLH1 (0.41) | KMT2AEPHX2TDP1 | |
| SCHEMBL18396048 | 0.90 | FOLH1 (0.41) | KMT2AEPHX2TDP1 | |
| SCHEMBL30031700 | 0.90 | FOLH1 (0.41) | KMT2AEPHX2TDP1 | |
| SCHEMBL18396046 | 0.90 | FOLH1 (0.41) | KMT2AEPHX2TDP1 | |
| SCHEMBL16010863 | 0.90 | FOLH1 (0.41) | KMT2AEPHX2TDP1 | |
| SCHEMBL29551974 | 0.89 | NOD1 (0.48) | GLP1RNOD1KMT2AL3MBTL1 | |
| SCHEMBL25963705 | 0.89 | TDP1 (0.43) | KMT2AL3MBTL1EPHX2TDP1 | |
| SCHEMBL18770775 | 0.89 | KMT2A (0.43) | GLP1RNOD1KMT2ATDP1 | |
| SCHEMBL22228935 | 0.89 | KMT2A (0.43) | GLP1RNOD1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338841-A1 | Imaging Agents | SCINTOMICS GMBH (DE) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338841-A1 | Imaging Agents | HNRNPF, ANXA5, TFEB | GLP1R 769/4885NOD1 600/4885KMT2A 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.